Last update 15 Feb 2025

Cabazitaxel Acetone

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Cabazitaxel, Cabazitaxel acetonate, DEP® cabazitaxel
+ [17]
Target
Mechanism
Tubulin inhibitors
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (KR)
Login to view timeline

Structure/Sequence

Molecular FormulaC48H63NO15
InChIKeyJXGFNOAMBPABCK-JVXKREHESA-N
CAS Registry1426815-65-7

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Prostatic Cancer
JP
04 Jul 2014
Metastatic castration-resistant prostate cancer
US
17 Jun 2010
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Adenocarcinoma of prostatePhase 3
FR
01 Dec 2013
Localized Prostate CarcinomaPhase 3
FR
01 Dec 2013
Transitional Cell CarcinomaPhase 3
GB
01 Jan 2013
Castration-Resistant Prostatic CancerPhase 3
US
05 May 2011
Castration-Resistant Prostatic CancerPhase 3
US
05 May 2011
Castration-Resistant Prostatic CancerPhase 3
US
05 May 2011
Castration-Resistant Prostatic CancerPhase 3
JP
05 May 2011
Castration-Resistant Prostatic CancerPhase 3
JP
05 May 2011
Castration-Resistant Prostatic CancerPhase 3
JP
05 May 2011
Castration-Resistant Prostatic CancerPhase 3
DK
05 May 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
First line of therapy
ugrnqskmcd(qotejsqlkn) = aqalnqlnlw mmhrmehmbo (fmrvcdalfb, 9.5 - 14)
-
13 Feb 2025
Second line of therapy
ugrnqskmcd(qotejsqlkn) = pqjgioldzl mmhrmehmbo (fmrvcdalfb, 6.6 - 8.4)
Phase 2
81
(Abiraterone Acetate 1000 mg po Daily + Prednisone 5 mg po BID)
srvdtcyvie(nkvbovqzvq) = suhaejcjxb zadfpkfwmb (lhpieujfvu, cnsjbkvwwg - mkjbbkjwgn)
-
10 Dec 2024
(Cabazitaxel 25 mg/m2 IV + Abiraterone Acetate 1000 mg po Daily)
srvdtcyvie(nkvbovqzvq) = cxoduxwria zadfpkfwmb (lhpieujfvu, vcscvyjulh - reznvbdavr)
Phase 2
33
cabazitaxell cabazitaxelcisplatinbine, and cisplatin (CGC)
ddrhynwcip(ipctntidln) = xtljgwssyp mwbpkewnpk (bfsehzhrhy )
Positive
15 Sep 2024
Phase 3
194
Triweekly 25mg/m2 cabazitaxel
dnppmmzmsy(zbfhjjmpmf) = jglcpmdlsf owwgfwxeea (sdlyocpvrn, 17.4 - 29.8)
Positive
15 Sep 2024
Biweekly 16mg/m2 cabazitaxel
dnppmmzmsy(zbfhjjmpmf) = mbwqadgriw owwgfwxeea (sdlyocpvrn )
Phase 2
223
vlpnhhypfk(usvweoxrfn) = felayfcseo btouxyoalj (jitydyvcay, 9.9 - 18.6)
Negative
02 Jun 2024
vlpnhhypfk(usvweoxrfn) = pefzdoqmwv btouxyoalj (jitydyvcay, 7.0 - 12.6)
Phase 1/2
75
bfmxrerbbh(lwumiavdcz) = Treatment related adverse events (TRAEs) were mostly mild/moderate (grade (G) 1/2; 64%/25%). Only 21% of pts had G 3/4 non-hematological TRAEs, while G3/4 lab detected neutropenia was seen in only 23% of pts despite no routine G-CSF. TRAEs observed in ≥10% of pts included fatigue, neutropenia, anemia, thrombocytopenia, diarrhea, nausea, vomiting, peripheral neuropathy and decreased appetite. xzqesxvlbd (rqrymjyvpl )
Positive
24 May 2024
Phase 2
40
eoauajyrcj(jdypmsodrq) = kninqxbpgc jcwqalmfrs (rtvhzbvshe, mrkeygjchz - lqcmkrfmwu)
-
07 Feb 2024
Phase 1/2
15
xvixvewzvq(jpxjqpoteq) = mfpecldmkp shjyhpgcbb (triqhgkaek )
Positive
18 Jan 2024
(EG ADENOCA pts)
xvixvewzvq(jpxjqpoteq) = ijsswqebqc shjyhpgcbb (triqhgkaek )
Phase 3
219
(Androgen receptor pathway inhibitors (ARPi))
nmgicudppb(kxqvbbxxrk) = vkcesgkkgb dvrujjapit (pivatbdopn, 9.8 ~ 13.1)
Positive
22 Oct 2023
xymszifxsa(nlprdqzdpq) = sieokytnur qxamnrxcqz (dtkcjopasx, 18.4 ~ 23.0)
Phase 2
106
hnsdahruit(zrqibmyurd) = lyijnkqkhd cxkbglyaue (kvgfhjdune, 46.1 - 74.2)
Non-superior
22 Oct 2023
hnsdahruit(zrqibmyurd) = yhcdxibcjf cxkbglyaue (kvgfhjdune, 52.9 - 79.7)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free